Choosing continued advanced medicines or colectomy for ulcerative colitis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a prospective observational cohort comparing patients with active ulcerative colitis who opt for continued advanced medical therapy to those who choose colectomy after failing at least two lines of advanced treatments. Participants eligible for both options will be followed with standardized quality-of-life, functional outcome, and patient satisfaction measures, along with clinical data from medical records. The design captures real-world decision-making and outcomes rather than randomizing treatment, aiming to reflect typical patient and clinician choices. Findings will be used to inform shared decision-making between patients and providers.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients with UC with active disease
* failed at least two lines of advanced medical therapies
* are eligible for both continued AMT and colectomy

Exclusion Criteria:

* diagnostic uncertainty
* diagnosis of impaired cognitive function
* non-domestic and non-English speaking

Where it's running

• Karolinska University Hospital
  Solna, Stockholm County, Sweden Recruiting

Study contacts

• Principal investigator: Caroline Nordenvall, Ass. professor — Karolinska Institutet
• Study coordinator: Carl Kördel, MD, PhD-student
• Email: carl.kordel@ki.se
• Phone: +46702545871

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• MGT-006 safety and dosing study for ulcerative colitis

  This study tests an oral microbiome capsule called MGT-006 to see if it is safe and tolerable in adults with moderately active ulcerative colitis, and whether the gut bacteria engraft after treatment.

  Recruiting at 9 sites Phase 1/2 Metagen Therapeutics, Inc. · Naples, Florida and 11 other locations · NCT07913347

• PALI-2108 vs placebo for moderate to severe ulcerative colitis

  A phase 2 study to see if PALI-2108 helps people with moderate to severe ulcerative colitis more than a placebo.

  Recruiting at 28 sites Phase 2 Palisade Bio · Sun City, Arizona and 114 other locations · NCT07845487

• Nitazoxanide as an add-on therapy for mild-to-moderate ulcerative colitis

  A study tests whether adding nitazoxanide to standard UC treatment helps people with mild-to-moderate ulcerative colitis see more relief.

  Recruiting at 2 sites Phase 2/3 Tanta University · Tanta and 1 other locations · NCT07820046

• Fecal Transplants from Dai vs Han Donors for Ulcerative Colitis

  This study tests whether fecal microbiota transplantation from healthy Dai donors improves symptoms in adults with ulcerative colitis more than transplantation from healthy Han donors.

  Recruiting Phase 2 First Affiliated Hospital of Kunming Medical University · Kunming, Yunnan · NCT07814456

• Familial IBD Early Risk

  This study tests whether clinical, environmental, and immune factors in first-degree relatives of people with Crohn’s disease or ulcerative colitis can predict who will develop IBD.

  Recruiting Seattle Children's Hospital · Seattle, Washington · NCT07791862

• Probiotics and Trace Elements Added to Infliximab in Ulcerative Colitis

  This trial tests whether adding a Lactobacillus probiotic or trace elements to infliximab helps people with ulcerative colitis stay in remission.

  Recruiting Phase 4 National Hepatology & Tropical Medicine Research Institute · Cairo · NCT07758335

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.